Younger Women May Face Worse Ovarian Cancer Outcomes After Primary Therapy

Share this content:
Women with low-grade serous carcinoma of the ovary or peritoneum who are under the age of 35 face worse outcomes.
Women with low-grade serous carcinoma of the ovary or peritoneum who are under the age of 35 face worse outcomes.

Upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

David Gershenson, MD, and fellow researchers at the University of Texas MD Anderson Cancer Center in Houston, TX, evaluated 350 patients who were diagnosed with stage 1 to 4 LGSOC or LGSPC before January 2012.

“LGSOC or LGSPC is a rare subtype of ovarian or peritoneal cancer characterized by young age at diagnosis and relative resistance to chemotherapy,” the authors noted. They hoped to validate these findings in the current study.

Upon multivariate analysis, the researchers found that women over the age of 35 had a 43% reduced likelihood of dying compared to those 35 and younger.

RELATED: Reduced Chemotherapy Doses Linked to Decreased Survival in Ovarian Cancer

Additionally, having disease present upon completion of primary therapy was associated with a 1.78 increased hazard of dying compared to being clinically disease-free.

Women with LGSPC were found to have a 41% decreased likelihood of dying compared to those with LGSOC. “Patients with LGSPC seem to have a better prognosis than those with LGSOC,” the authors concluded.

Reference

  1. Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. Journal of Clinical Oncology. [epub ahead of print]. doi: 10.1200/JCO.2015.61.0873.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs